Bionic Spółka z Ograniczoną Odpowiedzialnością (KRS 0000836852, NIP 5842792671) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. BIONIC operates in: Retail sale via mail order houses or via Internet (PKD 47.91.Z). Industry: Retail trade. The company has been listed in the National Court Register since April 3, 2020. BIONIC's most recently reported net revenue was 29.7 M PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Bionic
Identity
- Name
- Bionic Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- April 3, 2020
- Registry status as of
- November 21, 2025
- Latest entry
- July 7, 2025
- Founding act
- 01.04.2020R.
Articles of association history (2)
- April 1, 2020: 01.04.2020R.
- March 31, 2022: 31.03.2022 ZMIANA §4
Activities
Main activity
47.91.ZRetail sale via mail order houses or via Internet
Other activities
Address and contact
- Address
- ALEJA GRUNWALDZKA, 415, 80-309, GDAŃSK, POLSKA
- Voivodeship
- POMORSKIE
- District
- GDAŃSK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-66030-89510-GUUWR-15
- Coordinates
- 54.3598, 18.6360approx.
Risk and payment profile - Bionic
Credibility rating
70.5 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/6 yrs
Board changes
0
0/6 yrs
PKD changes
1
1/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: B (71/100)
Trend: improving (+9.9 pts/year)
High payment credibility - the company's financial condition is good and the risk of cooperating with it is low.
Trade credit limit history
Standard limit from 2020–2024
Current: 844.0 K PLN
Safe: 548.6 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Bionic
Founded
April 3, 2020
6 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
47.91.Z
Retail sale via mail order houses or via Internet
Share capital
5.0 K PLN
50 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
5 years
2020–2024
Registry entries
18
latest: July 7, 2025
Revenue
29.7 M PLN
2024
Net profit
502.1 K PLN
2024
Assets
2.0 M PLN
2024
Equity
N/A
2024
EBITDA
394.8 K PLN
2024
Valuation
3.7 M PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Bionic.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
